Anthropic Life Sciences Head Eric Kauderer-Abrams says the AI startup set up a Bay Area wet lab for physical biology work, as it pushes into disease treatment

AI models can now automate the execution of physical lab experiments for scientific discovery.

AI startup Anthropic has established a new biology research laboratory in the San Francisco Bay Area, confirmed by Eric Kauderer-Abrams, the company's Head of Life Sciences. The lab is dedicated to conducting physical experiments, with Kauderer-Abrams emphasizing the necessity of real-world lab work for biological research. While Anthropic has launched a drug discovery program called Claude Science and expressed interest in tackling financially unviable research, a spokesperson indicated the lab's purpose extends beyond just drug discovery. The company is exploring how AI can accelerate the development of treatments for complex conditions. Sources suggest Anthropic is investigating using its AI, Claude, to control robots for scientific experiments, though Kauderer-Abrams noted this automation is in its early stages and human oversight is crucial. Anthropic has not yet conducted any clinical trials and faces public trust issues, similar to other AI firms, following an incident where it stopped scientists attempting to create biological weapons with its AI.

Anthropic's move into physical biology research signals a significant push by AI companies beyond pure software and into tangible scientific applications. By establishing a wet lab, Anthropic is positioning itself to directly address complex biological challenges, potentially accelerating drug discovery and treatment development in areas previously deemed too difficult or unprofitable for traditional pharma. This integration of AI with hands-on experimentation could redefine the pace and scope of biomedical innovation.

The creation of this lab, coupled with potential applications like controlling robots for experiments, suggests a future where AI agents operate sophisticated laboratory workflows. This development impacts the pharmaceutical and biotech industries by offering a novel approach to research and development, potentially reducing costs and timelines. For AI researchers and developers, it represents a new frontier for applying artificial intelligence to solve real-world, physical problems, albeit with significant safety and ethical considerations to manage.